Mi az ára Freeline Therapeutics Holdings plc (FRLN)

Freeline Therapeutics Holdings plc (FRLN) ára $6.48

Mi a Freeline Therapeutics Holdings plc (FRLN piaci tőkésítése)

Freeline Therapeutics Holdings plc piaci tőkésítése (FRLN) $15.41M

Freeline Therapeutics Holdings plc (FRLN) Nyereség

Freeline Therapeutics Holdings plc is a biopharmaceutical company, currently in its clinical development phase, focused on creating groundbreaking gene therapies. These innovative treatments leverage adeno-associated virus (AAV) vector technology to tackle inherited, systemic, and severely debilitating genetic conditions. The company's leading therapeutic candidate, verbrinacogene setparvovec (FLT180a), is presently undergoing Phase 1/2 clinical trials for the management of hemophilia B in adult males. Furthermore, Freeline's pipeline features FLT190, which is also in Phase 1/2 clinical evaluation for treating Fabry disease, and FLT201, a gene therapy designed to target the liver for type 1 Gaucher disease, likewise progressing through Phase 1/2 trials. Beyond these specific programs, the company is actively pursuing research initiatives across a range of other systemic gene therapy indications. Freeline was established in 2015 and operates from its headquarters in Stevenage, United Kingdom.

Év	Nyereség	Változtassa meg
Nincs elég adat a megadott dátumokhoz.

Év

Nyereség

Változtassa meg

Nincs elég adat a megadott dátumokhoz.

Vállalat	Nyereség	Nyereségkülönbség	Ország
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	$3.01B	-	BE

Vállalat

Nyereség

Nyereségkülönbség

Ország